Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC

NCT03041311 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

107

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Cancer

Interventions

DRUG: Trilaciclib
DRUG: Placebo
DRUG: Carboplatin
DRUG: Etoposide
DRUG: Atezolizumab

Sponsor

G1 Therapeutics, Inc.

Collaborators

[object Object]